Taxane-based regimens are among the preferred first-line chemotherapy options for metastatic breast cancer, with weekly paclitaxel considered equivalent to 3-weekly docetaxel. The CALGB 40502/NCCTG N063H (Alliance) trial has now compared bevacizumab plus weekly paclitaxel, nab-paclitaxel, or ixabepilone in this setting; ixabepilone was inferior and nab-paclitaxel was not superior, with a trend towards inferiority. Paclitaxel thus remains the standard-of-care taxane chemotherapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Cardoso, F. et al. ESO–ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Ann. Oncol. 25, 1871–1888 (2014).
Partridge, A. H. et al. Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J. Clin. Oncol. 32, 3307–3329 (2014).
Rugo, H. S. et al. Randomized phase III trial of paclitaxel once per week compared with nanoparticle albumin-bound nab-paclitaxel once per week or ixabepilone with bevacizumab as first-line chemotherapy for locally recurrent or metastatic breast cancer: CALGB 40502/NCCTG N063H (Alliance). J. Clin. Oncol. 33, 2361–2369 (2015).
Ghersi, D. et al. Taxane-containing regimens for metastatic breast cancer. Cochrane Database of Systematic Reviews, Issue 6. Art. No.: CD003366 http://dx.doi.org/10.1002/14651858.CD003366.pub3 (2015).
Gradishar, W. J. et al. Phase II trial of nab-paclitaxel compared with docetaxel as first-line chemotherapy in patients with metastatic breast cancer: final analysis of overall survival. Clin. Breast Cancer 12, 313–321 (2012).
Gligorov, J. & Lotz, J. P. Preclinical pharmacology of the taxanes: implications of the differences. Oncologist 9 (Suppl. 2), 3–8 (2004).
Rugo, H. S. et al. A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer. Breast Cancer Res. Treat. 139, 411–419 (2013).
Miller, K. et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 357, 2666–2676 (2007).
Bonneterre, J. et al. Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure. Br. J. Cancer 87, 1210–1215 (2002).
Vahdat, L. T. et al. Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized phase II study comparing the incidence of peripheral neuropathy. Breast Cancer Res. Treat. 140, 341–351 (2013).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Gligorov, J., Richard, S. Weekly paclitaxel—still preferred first-line taxane for mBC. Nat Rev Clin Oncol 12, 508–509 (2015). https://doi.org/10.1038/nrclinonc.2015.137
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2015.137
